Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

IRVINE, Calif., June 25, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001.  The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

"There is a significant unmet need for effective and well-tolerated agents in the treatment of both atherosclerosis and lipid modulation," said Thomas W. Gardner, Chairman and Chief Executive Officer of AtheroNova.  "Based on AHRO-001's preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile.  We look forward to assessing AHRO-001 in human trials and are extremely pleased to have met a significant milestone with transitioning into a clinical stage company."

The Phase 1 study is a randomized, double-blind, placebo controlled study that assesses ascending doses of AHRO-001 in healthy adult volunteers.  The program advanced into Phase 1 clinical testing following extensive successful preclinical studies with AHRO-001.

"This is clearly an exciting and transformative time for us," remarked Mark K. Wedel, MD, Chief Medical Officer of AtheroNova.

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AtheroNova has shown positive results in animal models for regression of pl
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015  Delcath Systems, Inc. (NASDAQ: ... company focused on oncology with an emphasis on the ... two abstracts summarizing data from studies in ... the Delcath Hepatic CHEMOSAT ® Delivery System (CHEMOSAT) will ... Oncology (EADO) annual congress, which will be held in ...
(Date:8/4/2015)... DIEGO , Aug. 4, 2015 ... three-dimensional biology company focused on delivering scientific and ... that the Company has hired Paul Gallant ... vitro tissue service and product business. Mr. Gallant has ... experience in the drug discovery industry, most recently ...
(Date:8/4/2015)... , Aug. 4, 2015  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: ... and epigenetic drivers of cancer, will be presenting at the ... at 1:55 p.m. ET (10:55 a.m. PT) in ... Ph.D., president and CEO of Mirati, will provide a corporate ... will be accessible on the "Investors" page of Mirati,s corporate ...
Breaking Medicine Technology:Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... Designs, a company specializing in fashionable medical ID bracelets ... available in an additional 1,100 pharmacies by the end of ... products to more than 1,800. The company ... offering stylish key chains, necklaces, flash drives and bracelets available ...
... 2011 A new prostate cancer study ... surgical treatment to "watchful waiting" revealed important findings ... currently debating their treatment options. (Photo:   ... offered clinical options for early prostate cancer treatment ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 3
(Date:8/4/2015)... ... August 05, 2015 , ... ... Stevens as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
(Date:8/4/2015)... ... August 05, 2015 , ... The Journal of Pain ... ”. , As corresponding author Professor Akiko Okifuji says “Both obesity and chronic pain ... is not to say that one causes the other. Rather, there appear to be ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... technology platform that uses Cloud innovation to consolidate oncology patient assistance programs. Through ... a single point of access. assistPoint is an enterprise level, cloud-based application and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health ... echocardiogram, and NCV testing, announced their collegiate division, Wimbledon U , continues ... abnormalities one program at a time. , “Wimbledon U welcomes the ...
(Date:8/4/2015)... ... , ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp in ... that have a flip-up face shield. The sleek contours of the new Nightstick ... remove their headlamp when raising or lowering their face shield or visor. The 4614 ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3
... CREEK, Fla., Feb. 26 AlertSite(R), a leading,provider ... businesses,ensure optimum web experiences for their customers, announced ... site monitoring service.,iHerb.com is a major online retailer ... was recently name by ConsumerLab.com as the #1 ...
... Sponsorship of the 6th Annual Medical Banking Institute, highlights company,s ... ... and services platform, DALLAS, Feb. 26 BancTec, a ... is joining with,other industry leaders in an effort to improve ...
... as a Service, Innovation and Customer-Focused Approach to ... Artromick International, Inc.,a leading developer of medication ... acute care markets, today announced Edwin,Miller has joined ... Group.,In his new role, Miller is responsible for ...
... NEW YORK, Feb. 26 With over five million ... million new cases,diagnosed every year, it is the number ... accounting for a yearly direct cost of care,estimated at ... Failure: Worldwide Device Markets., Improvements in the care ...
... Capabilities, and New Architecture Position Solution as ... Market Leader, STAMFORD, ... the latest update to its Order Sets,Solution, which now includes:, ... market. -- Tools to create, edit, and maintain large ...
... Rx, a,wholly owned subsidiary of TeamStaff, Inc. ... Seal of Approval(TM) for health care staffing ... Healthcare Organizations ("JCAHO")., The JCAHO review ... processes, performance evaluations, education processes,and information management ...
Cached Medicine News:Health News:Top Nutritional Supplement Online Retailer, iHerb.com, Selects AlertSite for Web Site Performance Monitoring 2Health News:BancTec Takes Leadership Position in Helping to Create Better Value, Lower Transaction Costs in Healthcare Industry 2Health News:BancTec Takes Leadership Position in Helping to Create Better Value, Lower Transaction Costs in Healthcare Industry 3Health News:Artromick Names Edwin Miller President of Software Products Group 2Health News:'Hidden Epidemic' of Congestive Heart Failure Driving Hospitalization, Costs 2Health News:Thomson Healthcare Announces Enhancements to Order Sets Solution 2Health News:Thomson Healthcare Announces Enhancements to Order Sets Solution 3Health News:TeamStaff Rx Awarded JCAHO Certification 2Health News:TeamStaff Rx Awarded JCAHO Certification 3
... is a unique microprocessor controlled shaking incubator ... either 96 or 384 well format. Speed, ... control panel and all are displayed on ... the clear protective cover. The Millennium 2000 ...
... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
... Ultracompact high end desktop multilaser flow ... any kind of cell analysis and absolute ... forward and two different side scatter signals ... channels. The new CyFlow ML instrument can ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: